Table II.
Time (h) | Treatment | PSGL-1 levels | |
---|---|---|---|
IL-1β | IL-1β + cmpd 1 | ||
0 | 16.7 ± 6.6 | 16.7 ± 6.6 | MFI |
24 | 13.9 ± 2.1 | 8.4 ± 1.3 | MFI |
48 | 22.2 ± 3.7 | 10.4 ± 2.1 | MFI |
72 | 44.2 ± 10.0 | 13.8 ± 4.1 | MFI |
Time (h) | Treatment | PSGL-1 levels | |
---|---|---|---|
IL-1β | IL-1β + cmpd 1 | ||
0 | 16.7 ± 6.6 | 16.7 ± 6.6 | MFI |
24 | 13.9 ± 2.1 | 8.4 ± 1.3 | MFI |
48 | 22.2 ± 3.7 | 10.4 ± 2.1 | MFI |
72 | 44.2 ± 10.0 | 13.8 ± 4.1 | MFI |